China Resources Sanjiu Medical & Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
China Resources Sanjiu Medical & Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) has a cash flow conversion efficiency ratio of 0.067x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥2.60 Billion ≈ $380.73 Million USD) by net assets (CN¥38.77 Billion ≈ $5.67 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of China Resources Sanjiu Medical & Pharmaceutical Co Ltd (1999–2025)
Cash flow conversion efficiency of China Resources Sanjiu Medical & Pharmaceutical Co Ltd from 1999 to 2025. This chart illustrates how China Resources Sanjiu Medical & Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of China Resources Sanjiu Medical & Pharmac for real-time trading data and today's change.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
China Resources Sanjiu Medical & Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China Resources Sanjiu Medical & Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see China Resources Sanjiu Medical & Pharmac (000999) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YANGTZE OPT.FIB.AND CAB.H
F:1YO
|
N/A |
|
Bank of Suzhou
SHE:002966
|
0.008x |
|
Schaeffler AG
XETRA:SHA0
|
0.042x |
|
VSXY
NYSE:VSXY
|
-0.162x |
|
Haohua Chemical Science & Technology Corp Ltd
SHG:600378
|
0.029x |
|
Indian Overseas Bank
NSE:IOB
|
-0.682x |
|
Inner Mongolia Xingye Mining Co Ltd
SHE:000426
|
0.095x |
|
Hebei Yangyuan ZhiHui Beverage Co Ltd
SHG:603156
|
-0.058x |
Annual Cash Flow Conversion Efficiency for China Resources Sanjiu Medical & Pharmaceutical Co Ltd (1999–2025)
The table below shows the annual cash flow conversion efficiency of China Resources Sanjiu Medical & Pharmaceutical Co Ltd from 1999 to 2025. Review 000999 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥38.77 Billion ≈ $5.67 Billion |
CN¥5.51 Billion ≈ $806.74 Million |
0.142x | -18.42% |
| 2024-12-31 | CN¥25.26 Billion ≈ $3.70 Billion |
CN¥4.40 Billion ≈ $644.18 Million |
0.174x | +0.89% |
| 2023-12-31 | CN¥24.26 Billion ≈ $3.55 Billion |
CN¥4.19 Billion ≈ $613.38 Million |
0.173x | +0.76% |
| 2022-12-31 | CN¥17.53 Billion ≈ $2.57 Billion |
CN¥3.01 Billion ≈ $439.93 Million |
0.171x | +43.52% |
| 2021-12-31 | CN¥15.77 Billion ≈ $2.31 Billion |
CN¥1.88 Billion ≈ $275.78 Million |
0.119x | -24.51% |
| 2020-12-31 | CN¥14.05 Billion ≈ $2.06 Billion |
CN¥2.22 Billion ≈ $325.44 Million |
0.158x | +4.98% |
| 2019-12-31 | CN¥13.08 Billion ≈ $1.91 Billion |
CN¥1.97 Billion ≈ $288.54 Million |
0.151x | -11.89% |
| 2018-12-31 | CN¥11.17 Billion ≈ $1.63 Billion |
CN¥1.91 Billion ≈ $279.68 Million |
0.171x | +8.43% |
| 2017-12-31 | CN¥10.13 Billion ≈ $1.48 Billion |
CN¥1.60 Billion ≈ $233.95 Million |
0.158x | -1.12% |
| 2016-12-31 | CN¥8.72 Billion ≈ $1.28 Billion |
CN¥1.39 Billion ≈ $203.71 Million |
0.160x | -2.77% |
| 2015-12-31 | CN¥7.67 Billion ≈ $1.12 Billion |
CN¥1.26 Billion ≈ $184.35 Million |
0.164x | -3.04% |
| 2014-12-31 | CN¥7.00 Billion ≈ $1.02 Billion |
CN¥1.18 Billion ≈ $173.32 Million |
0.169x | -28.50% |
| 2013-12-31 | CN¥6.20 Billion ≈ $906.76 Million |
CN¥1.47 Billion ≈ $214.73 Million |
0.237x | +9.56% |
| 2012-12-31 | CN¥5.61 Billion ≈ $820.42 Million |
CN¥1.21 Billion ≈ $177.33 Million |
0.216x | +9.79% |
| 2011-12-31 | CN¥4.85 Billion ≈ $709.79 Million |
CN¥954.90 Million ≈ $139.73 Million |
0.197x | +9.81% |
| 2010-12-31 | CN¥4.73 Billion ≈ $692.38 Million |
CN¥848.28 Million ≈ $124.13 Million |
0.179x | -17.15% |
| 2009-12-31 | CN¥3.95 Billion ≈ $578.22 Million |
CN¥855.05 Million ≈ $125.12 Million |
0.216x | -33.91% |
| 2008-12-31 | CN¥3.41 Billion ≈ $498.95 Million |
CN¥1.12 Billion ≈ $163.36 Million |
0.327x | +60.02% |
| 2007-12-31 | CN¥2.96 Billion ≈ $432.89 Million |
CN¥605.30 Million ≈ $88.57 Million |
0.205x | +25.40% |
| 2006-12-31 | CN¥2.61 Billion ≈ $381.59 Million |
CN¥425.51 Million ≈ $62.26 Million |
0.163x | +1610.20% |
| 2005-12-31 | CN¥2.39 Billion ≈ $350.07 Million |
CN¥22.83 Million ≈ $3.34 Million |
0.010x | +103.03% |
| 2004-12-31 | CN¥2.29 Billion ≈ $334.78 Million |
CN¥-719.63 Million ≈ $-105.30 Million |
-0.315x | -3512.62% |
| 2003-12-31 | CN¥3.05 Billion ≈ $446.03 Million |
CN¥28.09 Million ≈ $4.11 Million |
0.009x | -94.48% |
| 2002-12-31 | CN¥2.97 Billion ≈ $434.90 Million |
CN¥496.12 Million ≈ $72.60 Million |
0.167x | +221.19% |
| 2001-12-31 | CN¥2.95 Billion ≈ $432.00 Million |
CN¥153.44 Million ≈ $22.45 Million |
0.052x | -44.15% |
| 2000-12-31 | CN¥2.87 Billion ≈ $419.64 Million |
CN¥266.86 Million ≈ $39.05 Million |
0.093x | +104.71% |
| 1999-12-31 | CN¥2.65 Billion ≈ $388.31 Million |
CN¥120.63 Million ≈ $17.65 Million |
0.045x | -- |
About China Resources Sanjiu Medical & Pharmaceutical Co Ltd
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers health consumer products (CHC), including cold, flu, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug prod… Read more